Yahoo · Oct 9, 2026
Thermo Fisher Scientific's Q3 2026 Earnings: What to Expect
Thermo Fisher Scientific is poised to release its third-quarter results later this month, and analysts project a double-digit earnings rise.
NYSE · TMO
Thermo Fisher Scientific Inc.
Healthcare · Medical - Diagnostics & Research
$658.02
Up+$6.04 (+0.93%)
Updated Oct 11, 2026, 12:54 PM
SID Score
7.4/10
Composite research score
Smart Money
46/100
Neutral
- Market cap
- 219.39B
- P/E ratio
- 33.3
- Dividend yield
- 0.32%
- 52-week range
- $435.27 – $694.33
- Volume
- 1.58M
- Avg. volume
- 2.05M
Price performance · TMO
TMO price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
TMO closed at $658.02 after 20 trading sessions, up 7.24% for the selected period.
- Last close
- $658.02
- Period change
- +7.24%
- Period low
- $613.62
- Period high
- $679.61
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $650.00 | $661.94 | $644.1605 | $658.02 | 1.58M |
| Oct 8, 2026 | $657.53 | $658.56 | $635.32 | $651.98 | 2.59M |
| Oct 7, 2026 | $662.40 | $671.665 | $651.12 | $662.06 | 1.83M |
| Oct 6, 2026 | $683.35 | $694.325 | $654.51 | $656.58 | 2.75M |
| Oct 5, 2026 | $648.04 | $676.76 | $648.04 | $676.76 | 2.12M |
| Oct 2, 2026 | $654.15 | $659.47 | $648.29 | $654.80 | 1.67M |
| Oct 1, 2026 | $672.39 | $673.12 | $651.77 | $652.51 | 2.38M |
| Sep 30, 2026 | $675.95 | $683.63 | $671.63 | $675.05 | 2.32M |
| Sep 29, 2026 | $676.42 | $681.38 | $670.895 | $679.61 | 1.85M |
| Sep 28, 2026 | $668.02 | $682.61 | $664.23 | $678.60 | 1.91M |
| Sep 25, 2026 | $677.53 | $678.00 | $664.53 | $675.00 | 2.1M |
| Sep 24, 2026 | $660.91 | $682.98 | $655.95 | $678.39 | 2.1M |
| Sep 23, 2026 | $657.61 | $671.47 | $655.7803 | $665.30 | 2.35M |
| Sep 22, 2026 | $656.41 | $662.87 | $651.54 | $658.52 | 2.11M |
| Sep 21, 2026 | $653.89 | $660.44 | $649.1201 | $658.76 | 2.3M |
| Sep 18, 2026 | $656.61 | $660.10 | $646.805 | $651.45 | 4.58M |
| Sep 17, 2026 | $656.75 | $663.57 | $649.00 | $658.32 | 4.2M |
| Sep 16, 2026 | $642.00 | $653.40 | $638.00 | $648.43 | 2.88M |
| Sep 15, 2026 | $615.47 | $641.97 | $613.95 | $641.39 | 3.02M |
| Sep 14, 2026 | $614.94 | $616.00 | $605.65 | $613.62 | 1.27M |
Latest TMO news
The latest Smart Investors Daily articles mentioning TMO.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TMO research
Overview
Company profile and research snapshot.
Company profile
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $625.78
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Overweight | — |
| Sep 3, 2026 | CLSA | Outperform | — |
| Jul 27, 2026 | Morgan Stanley | Overweight | — |
| Jul 27, 2026 | Piper Sandler | Neutral | — |
| Jul 24, 2026 | Barclays | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 8, 2026
What Could Thermo Fisher Scientific (TMO) Change With Its New Digital CMC Consortium?
Thermo Fisher Scientific (NYSE:TMO) has helped launch the Digital CMC Consortium to advance digital Chemistry, Manufacturing, and Controls for biopharma. The initiative brings together biopharma companies, technology providers, and regulators to work on shared digital standards for CMC data. The Consortium aims to support faster therapy development, more efficient regulatory reviews, and digital lifecycle management across drug programs. The creation of the Digital CMC Consortium is...
ChartMill · Oct 8, 2026
Which S&P500 stocks are gapping on Thursday?
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Thursday and stay ahead of the market trends.
Yahoo · Oct 8, 2026
Why Thermo Fisher Scientific (TMO) Is Back In The Spotlight
Thermo Fisher Scientific (TMO) just appeared in the headlines after its clinical research business signed a Study Start-Up Agreement with Quantum BioPharma to run a Phase 2 multiple sclerosis trial for Lucid-MS. For context, Thermo Fisher Scientific’s share price is at US$662.06, with a 30-day share price return of 7.87% and a 90-day gain of 26.18%, while the 1-year total shareholder return of 23.91% points to momentum that has been building rather than fading. Capitalize on the momentum...
AI research layers
Interpretive context generated from the platform’s current data sources.
Thermo Fisher Scientific Inc. Stock Performance
Thermo Fisher Scientific Inc. shares closed at $658.02, reflecting a daily decline of approximately 1.05%, per SID market data. Despite the session's pullback, the stock has demonstrated positive momentum across multiple timeframes, gaining 9.09% over the past month and 24.5% over the trailing three months, according to Massive/Polygon data. On a twelve-month basis, TMO has advanced 13.62%. The stock currently trades well above both its 50-day moving average of $626.41 and its 200-day moving average of $532.59, indicating a sustained uptrend. The 14-day relative strength index stands at 49.7, suggesting neutral momentum without overbought or oversold conditions. Thermo Fisher carries a beta of 0.902, reflecting slightly lower volatility than the broader market. Average daily trading volume sits at approximately 2.05 million shares, and the company commands a market capitalization of roughly $219.4 billion within the Healthcare sector.
Thermo Fisher Scientific Inc. Valuation Analysis
Thermo Fisher Scientific trades at a price-to-earnings ratio of 33.30, positioning it at a premium relative to the broader Healthcare sector, per SID market data. The company's price-to-book ratio stands at 4.29, reflecting the market's valuation of intangible assets and brand strength accumulated through strategic acquisitions. The PEG ratio registers at an elevated 577.17, suggesting that the current earnings multiple significantly exceeds near-term expected growth rates, according to SEC filings. Thermo Fisher offers a modest dividend yield of approximately 0.29%, consistent with its capital allocation strategy that prioritizes reinvestment and acquisitions over shareholder distributions. With a market capitalization of $219.4 billion, TMO remains one of the largest pure-play life sciences companies by market value. The premium valuation metrics reflect the company's dominant positioning across analytical instruments, laboratory equipment, and life sciences solutions end markets.
Smart Money Activity for TMO
Thermo Fisher Scientific's composite smart money score stands at 53 out of 100, registering a neutral signal, per SID market data. The institutional component scores a perfect 25 out of 25, indicating exceptionally strong conviction among large asset managers and funds. In contrast, insider activity scores 9.5 out of 25, reflecting a cautious stance from company executives. According to SEC Form 4 filings, there have been 20 insider transactions over the past 90 days, comprising 6 purchases and 14 sales, yielding a sell-to-buy ratio of approximately 2.3 to 1. Dark pool activity registers at 8.5 out of 25, suggesting below-average institutional accumulation through off-exchange venues. Congressional trading activity scores 10.0 out of 25, indicating moderate interest from lawmakers disclosed in required filings. The divergence between robust institutional ownership conviction and elevated insider selling activity presents a mixed signal for investors monitoring smart money positioning in TMO shares.
Thermo Fisher Scientific Inc. Earnings Outlook
Thermo Fisher Scientific has demonstrated consistent earnings outperformance in its most recently reported quarters, according to company earnings reports. In the quarter reported on April 23, 2026, TMO posted earnings per share of $5.44 against a consensus estimate of $5.23, delivering a positive surprise of $0.21 or approximately 4.0%. The subsequent quarter reported on July 23, 2026, showed further acceleration, with actual EPS of $6.03 exceeding the $5.71 estimate by $0.32, representing a beat of roughly 5.6%. Looking ahead, analysts project EPS of $5.71 for the quarter with results expected on July 22, 2026, and $6.40 for the quarter scheduled for reporting on October 21, 2026, per analyst estimates. The sequential estimate increase from $5.71 to $6.40 reflects anticipated seasonal strength and continued demand normalization across Thermo Fisher's diversified life sciences and diagnostics portfolio.
Wall Street Analyst Ratings for TMO
Wall Street consensus on Thermo Fisher Scientific remains broadly constructive, with the majority of recent analyst actions reflecting bullish positioning, per Wall Street analyst reports. Barclays has reiterated its Overweight rating on multiple occasions, most recently on October 7, 2026, and previously on July 24, 2026, maintaining consistent conviction in the company's growth trajectory. Morgan Stanley similarly maintained its Overweight rating on July 27, 2026, reinforcing the positive institutional view. CLSA initiated coverage on September 3, 2026, with an Outperform rating, adding a new bullish voice to the coverage universe. Piper Sandler represents the sole neutral stance among recent ratings, maintaining its Neutral position on July 27, 2026, according to SID consensus data. Of the five most recent analyst actions tracked, four carry bullish ratings while one remains neutral, resulting in an 80% positive skew. No analyst has issued an underweight or sell-equivalent rating during the reviewed period.
